SMSvetlana V. Mikhaylovna

Svetlana V. Mikhaylovna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svetlana V. Mikhaylovna has a total of 199 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of treatments for L-aromatic amino acid decarboxylase deficiency: from symptomatic therapy to precision intraputamenal gene therapy

    by D. A. Reshchikov, S. V. Mikhailova, E. E. Petryaikina, E. A. Putilina, S. V. Gorelikov, E. Yu. Zakharova, K. K. Gadzhieva, Д. А. Рещиков, С. В. Михайлова, Е. Е. Петряйкина, et al.

    L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disorder caused by biallelic versions in the DDC gene and resulting in severe dopamine and serotonin deficiency Until recently, treatment was limited to exclusively symptomatic approaches and did not influence the poor prognosis. This review provides a chronological reconstruction of the development of therapeutic strategies, from early ineffective pharmacological regimens to modern pathogenetic gene therapy using the recombinant adeno-associated viral vector AAV2hAADC. Particular attention is paid to the neurosurgical component: the transition from frame stereotaxy and isolated intraputamenal infusion to contactless neuronavigation and convection-enhanced delivery under MRI guidance. The Russian experience of implementing a frameless stereotactic technique at the Russian Children’s Clinical Hospital is separately reviewed. Key clinical studies confirming the efficacy and safety of the approach are discussed, as are regulatory milestones leading to the approval of eladocagen exuparvovec (Upstaza in Europe in 2022, Kebilidi in the USA in 2024) Prospects and unresolved issues, including the optimal therapeutic window and long-term safety, are addressed.

  • Open Access

    Clinical experience of treating 28 patients with Duchenne muscular dystrophy with the exon 45 skipping drug casimersen

    by A. A. Agafonova, Агафонова А. А., S. B. Artemyeva, Артемьева С. Б., D. V. Vlodavets, Влодавец Д. В., L. M. Kuzenkova, Кузенкова Л. М., L. I. Minaycheva, Минайчева Л. И., et al.

    Background. Duchenne muscular dystrophy (DMD) is an irreversible, progressive fatal genetic disorder caused by the absence of functional dystrophin protein in muscle due to mutations in the DMD gene. Exon-skipping therapy for DMD aims to increase the amount of functionally active protein dystrophin. Casimersen, a drug for skipping exon 45, is indicated for patients with certain deletions. Clinical studies have confirmed an increase in dystrophin levels and improved motor activity in patients with DMD treated with casimersen. Aim. To present the experience of treating patients with DMD who were eligible for exon 45 skipping therapy. Materials and methods. Twenty-eight patients with DMD who received exon 45 skipping therapy were observed. Patients were assessed for functional status, motor tests (Six-Minute Walk Test, North Star Ambulatory Assessment) dynamics, and respiratory function with dynamic assessment of functional vital capacity. Results. Most outpatients showed stabilization of their condition with preservation of the ability to move independently, improvement or stability in functional (Six-Minute Walk Test, North Star Ambulatory Assessment) and timed test indicators, as well as stabilization of upper limb function and absence of progression of respiratory function decline in non-ambulatory patients. Conclusion. The safety and tolerability of casimersen therapy were generally good in all patients with DMD in our sample. All patients who initiated casimersen therapy in the early outpatient stage remained in this stage at the analysis date.

  • Open Access

    Practical aspects of intracerebroventricular infusions of cerliponase alfa in patients with neuronal ceroid lipofuscinosis type 2

    by Svetlana V. Mikhaylova, Михайлова Светлана Витальевна, V. S. Lobanova, Лобанова В. С., D. A. Reshchikov, Рещиков Д. А., P. V. Lobankin, Лобанкин П. В.

    Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, autosomal recessive neurodegenerative disorder caused by mutations in the TPP1 gene, which lead to a decrease or complete loss of lysosomal tripeptidyl peptidase 1 enzyme activity. The classic form of CLN2 disease typically manifests between the ages of 2 and 4 years. Over time, there is a rapid and predictably severe progression of intellectual and motor deficits, loss of visual acuity, and an increased frequency of epileptic seizures refractory to antiepileptic therapy. In its natural course, the classic form of CLN2 disease leads to severe disability by 6–7 years of age and death on average during the 10th year of life. Currently, pathogenetic enzyme replacement therapy has been developed only for CLN2 disease, utilizing the drug cerliponase alfa. In Russia, children with CLN2 disease are provided with cerliponase alfa through funding from the “Circle of Kindness”, a state fund supporting children with severe life-threatening and chronic diseases, including rare (orphan) conditions. Cerliponase alfa cannot cross the blood-brain barrier and must be administered directly into the cerebrospinal fluid via intracerebroventricular (ICV) infusion through a surgically implanted reservoir and ventricular catheter. Infectious complications can result in missed ICV infusions, which, in turn, may adversely affect the efficacy of enzyme replacement therapy. To reduce the risk of infectious complications, strict adherence to aseptic rules is essential during patient preparation, as well as during and after the ICV infusion. These practical guidelines for performing ICV infusions of enzyme replacement therapy in patients with CLN2 disease have been developed to implement measures in clinical practice aimed at minimizing the risk of infectious complications and damage to ICV infusion devices.

  • Open Access

    Evaluation of the efficacy and safety of microdystrophin replacement therapy with delandistrogene moxeparvovec in patients with progressive Duchenne muscular dystrophy in real-life clinical practice

    by Svetlana V. Mikhaylova, M. E. Abdullina, N. A. Votyakova, M. V. Zazhivikhina, E. L. Usacheva, E. E. Petryaykina

    Progressive Duchenne muscular dystrophy is a severe progressive X-linked hereditary disease caused by mutations in the DMD gene encoding the dystrophin protein. The disease is characterized by early onset of muscle weakness in the proximal limbs, loss of the ability to walk independently, followed by damage to respiratory and cardiac functions, and premature death of patients in the second or third decade of life. Until recently, patients were prescribed only symptomatic treatment aimed at slowing down the progression of the disease. Currently, several pathogenetic drugs have appeared aimed at restoring the synthesis of the dystrophin protein (microdystrophin). One of them, delandistrogen moxparvovec, is gene therapy drug based on a recombinant adeno-associated virus (AAVhr74). The article presents the experience of using Delandistrogen moxparvovec in 17 patients with Duchenne muscular dystrophy aged 5 years 8 months to 9 years and 1 months. Preliminary data indicate a possible slowdown in the progression of the disease, which is manifested in stabilization or improvement of motor functions. In all patients, the use of this drug was safe, there were no adverse events associated with this therapy.

  • Open Access

    Frameless stereotactic infusion of gene therapy into the putamen for AADC deficiency in children: technical and organizational aspects of implementation in Russia

    by Dmitriy A. Reshchikov, R. B. Mai, S. V. Mikhaylova, S. V. Gorelikov, Е. Yu. Zakharova, E. E. Petryaykina, E. A. Putilina, V. V. Palm

    Aim. To present the authors’ experience in implementing a frameless stereotactic infusion technique of a gene preparation using an adeno-associated vectored virus into the subcortical structures of the brain in children with aromatic L-amino acid decarboxylase deficiency (AADCd), with an emphasis on technical and organizational aspects. Materials and methods. From November 2024 to December 2025, six bilateral infusions of eladocagen exuparvovec (Upstaza®) were administered into the putamen of children with genetically confirmed AADCd in the Department of Pediatric Neurosurgery of the Russian Children’s Clinical Hospital. The key stages of patient selection, regulatory support, preoperative planning based on brain magnetic resonance imaging data, features of frameless navigation, the Z-shaped convection-enhanced infusion technique, and measures for preventing intra- and postoperative complications are described. The analysis of clinical outcomes is deliberately not presented in this work and is planned for a separate publication after increasing the sample size and follow-up observation. Results. In all 6 cases, accurate drug delivery to the putamen was ensured in accordance with preoperative planning, and no intraoperative complications were observed. Early postoperative magnetic resonance imaging monitoring revealed no clinically significant hemorrhagic or ischemic brain damage. In all cases, improvements in motor and autonomic symptoms of varying severity were noted during the first months of follow-up. Conclusion. The presented experience demonstrates the technical feasibility and safety of frameless stereotactic gene therapy for AADCd in children in a Federal Center setting. The proposed method can serve as the basis for a national treatment protocol for AADCd and the establishment of a reference center for gene therapy for central nervous system diseases.


  • Open Access

    A case of using specialized medical nutrition product containing anhydrous betaine in patient with homocystinuria

    by Anna A. Agafonova, Svetlana V. Mikhaylovna, Natalya A. Votyakova, Mayya V. Zazhivikhina, Larisa I. Minaycheva, Gulnara N. Seitova, Вотякова Наталья Александровна, Заживихина Майя Владимировна

    BACKGROUND: Although homocystinuria is a rare disorder, its management remains an important issue in modern pediatrics. Diet therapy is the main pathogenetic treatment for patients with homocystinuria. The use of betaine as part of combination therapy helps reduce plasma homocysteine concentrations, particularly in patients who do not respond to other treatment approaches. A CASE REPORT: A 12-year-old child with genetically confirmed pyridoxine-responsive homocystinuria underwent substitution of an imported preparation containing anhydrous betaine with a specialized medical nutrition product, Amino Acid Module Betaine (ORPHANIC® trademark). The previously effective combination therapy regimen remained unchanged. CONCLUSION: Replacement of anhydrous betaine within the previously established treatment regimen, followed by 30 days of administration of the medical nutrition product Amino Acid Module Betaine (ORPHANIC® trademark) containing betaine anhydrous, demonstrated a good safety profile. This substitution did not significantly affect the patient’s general condition, disease course, or key parameters of sulfur-containing amino acid metabolism. Prescription of the medical nutrition product Amino Acid Module Betaine (ORPHANIC® trademark) containing anhydrous betaine, or transition of a patient to this product, requires monitoring of the patient’s general condition and regular determination of sulfur-containing amino acid metabolism parameters. This study represents the first clinical evaluation of anhydrous betaine produced in Russia. The obtained results indicate its efficacy and safety in the treatment of a patient with homocystinuria.

  • Open Access

    Modern Clinical Guidelines for the Management of Patients with Gaucher Disease

    by Inga V. Anisimova, Galina V. Baydakova, Aleksander A. Baranov, Nato D. Vashakmadze, Elena A. Vishneva, Olga S. Gundobina, Elena A. Dobrynina, Ekaterina Yu. Zaharova, Elena V. Kaytukova, Kutsev Sergey I, et al.

    This article presents data on the epidemiology, pathogenesis, modern classification and the main clinical manifestations of Gaucher disease in children. The criteria for differential diagnosis with other diseases are given. It has been shown that the only effective method of treating Gaucher disease is pathogenetic enzyme replacement therapy, which relieves the main clinical manifestations of the disease, improving the quality of life of patients and without having pronounced side effects. The main errors of diagnosis and management of patients, as well as unjustified prescriptions for the treatment of this disease, are indicated.

  • Difficulties in diagnosing pyruvate dehydrogenase complex deficiency based on clinical and biochemical data: series of clinical case reports

    by S.V. Mikhaylova, E.YU. Zakharova, M.V. Zazhivikhina, N.A. Votyakova, M.E. Abdullina, P.G. Tsygankova, Yu.B. Yurasova, Moscow N.N. Priorov National Medical Center Of Traumatology And Orthopedics Of The Ministry Of Healthcare Of Russia, E.L. Usacheva, E.E. Petryaykina

    Pyruvate dehydrogenase complex deficiency (PDC) is a mitochondrial disease associated with a violation of pyruvate metabolism and leading to a decrease in ATP production. PDC is responsible for the decarboxylation of pyruvate into acetyl-CoA. PDC deficiency can be caused by changes in any of the genes encoding its subunits. The clinical phenotype is very variable, mainly the central nervous system is affected. Diagnosis of the disease can cause significant difficulties due to the rarity of the pathology, the lack of specificity of clinical symptoms and pronounced clinical polymorphism. The purpose of this research was to describe and discuss the clinical, biochemical and genetic data of six recently observed patients with PDC deficiency who were identified in Russia. Authors have analyzed the clinical manifestations of a rare progressive pathology from the group of mitochondrial diseases caused by pathogenic variants of the nuclear X-linked PDHA1 gene (encodes the alpha subunit of pyruvate dehydrogenase) in six patients aged 8 to 120 months old. By the time of examination in the hospital the main clinical symptoms included as follows: delayed psychomotor development, epileptic seizures, severe delay in psychomotor development and - in a single patient - depression of consciousness to coma, the status of epileptic seizures and an unfavorable outcome. In all patients, magnetic resonance imaging (MRI) of the brain revealed changes as follows: cortical atrophy in all 6 patients, basal ganglia lesion in three cases, congenital brain defects in 3 patients and multicystic lesion in a single patient. All children had high lactate levels. Pathogenic variants of the PDHA1 gene were detected in all 6 children and on this basis the diagnosis was confirmed. As a result of treatment, 5 of the 6 children showed moderate positive dynamics as follows: a decrease in the frequency of epileptic seizures and lactate in the blood, improvement in psychomotor development and - in a single patient - a fatal outcome as a result of late diagnosis and rapidly progressing clinical symptoms. Conclusion: Authors have described the clinical characteristics of PDC in recent cases such as: age of manifestation, the disease course nature, results of molecular genetic studies. Clinical polymorphism in patients with this rare pathology was shown as well. The Article may be of great help to pediatricians, neurologists and geneticists in improving the diagnosis of PDC deficiency.

  • Hereditary hypomagnesemias in children: pathogenesis, clinical picture and treatment approaches

    by S.V. Mikhailova, E.YU. Zakharova, Yu.B. Yurasova, Moscow N.N. Priorov National Medical Center Of Traumatology And Orthopedics Of The Ministry Of Healthcare Of Russia, E.E. Petryaykina

    Hypomagnesaemias are the diseases characterized by the reduced level of magnesium in the body. The first mention of them appeared in the early XX century when cases in children were initially described as conditions accompanied by painful twitching in the muscles, weakness and heart rhythm disturbances, the reasons for which remained unknown for a long time. The scientific research in recent decades has only made it possible to decipher the diseases’ pathogenesis mechanisms. Primary hypomagnesaemias are hereditary monogenic diseases in which, as a result of a violation of magnesium metabolism in the body, its concentration decreases and the main clinical manifestations of the disease develop. The clinical picture of hypomagnesemia in children can be diverse and nonspecific. Early symptoms are manifested in the form of short-term involuntary painful contractions of muscles or muscle groups, weakness, cardiac arrhythmia and fatigue. As the disease progresses, more rather serious symptoms such as stunted growth, psychomotor development and epileptic seizures may occur. The severity of clinical manifestations of hereditary hypomagnesaemias correlates with the degree and duration of magnesium deficiency: from general weakness and crumpy syndrome to the development of depression of consciousness and in some cases of an unfavorable outcome. The main methods for confirmatory diagnosis of genetically determined hypomagnesaemias are molecular genetic methods. Authors represent bibliographical review and recent updates on known primary hypomagnesaemias in terms of mechanisms of pathogenesis and clinical presentation as well as their own familial case description of hypomagnesaemia in children.


  • Allogeneic hematopoietic stem cell transplantation in a pediatric patient with alpha-mannosidosis

    by E.B. Machneva, A.V. Mezentseva, A.E. Burya, L.V. Olkhova, M.S. Kuritsyna, Yu.а. Nikolaeva, E.A. Pristanskova, S.V. Mikhailova, E.V. Skorobogatova

    Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.